GlassScriptPhysician profile
Joanne M Richards
NPI 1659454478
$3,491.68
in general payments reported to CMS, 2019-2025
38 companies · $422 in 2025
The $422 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $188 · 2021: $553 · 2022: $749 · 2023: $259 · 2024: $353 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $736.72 | 2019-2025 | Slynd |
| Abbvie INC. | $336.18 | 2019-2023 | |
| Gynesonics, INC. | $271.60 | 2022 | |
| Coopersurgical, INC. | $260.38 | 2019-2025 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Mayne Pharma Commercial LLC | $213.83 | 2021-2024 | |
| Therapeuticsmd, INC. | $198.48 | 2019-2022 | |
| Astellas Pharma US INC | $112.70 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $109.66 | 2020-2023 | Aptima, Affirm Prone Biopsy System |
| Pfizer INC. | $103.61 | 2022-2025 | |
| Agile Therapeutics, INC. | $99.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.60 | 2019-2022 | |
| Organon LLC | $89.60 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $85.61 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $73.79 | 2021-2022 | |
| Smith+Nephew, INC. | $69.85 | 2024-2025 | Pico 14 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $65.51 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Shield Therapeutics INC | $56.02 | 2024-2025 | |
| Solventum Corporation | $47.42 | 2024-2025 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Scynexis, INC. | $44.77 | 2022 | |
| Avion Pharmaceuticals | $37.31 | 2020-2022 | |
| Daiichi Sankyo INC. | $36.39 | 2019 | |
| Biogen, INC. | $34.97 | 2025 | Zurzuvae |
| Intuitive Surgical, INC. | $33.05 | 2019 | |
| Aspira Women'S Health INC | $28.12 | 2019 | |
| Dexcom, INC. | $26.60 | 2025 | Dexcom G6 Transmitter |
| Lupin INC. | $25.59 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $23.27 | 2019 | |
| Roche Diagnostics Corporation | $21.17 | 2021 | |
| Mylan Pharmaceuticals INC. | $20.74 | 2021 | |
| Innovation Technologies INC | $20.37 | 2025 | Irrisept |
| Baxter Healthcare | $19.29 | 2025 | Perclot |
| Meditrina | $17.31 | 2021 | |
| Kerecis Limited | $16.83 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Allergan, INC. | $16.32 | 2020 | |
| Amgen INC. | $16.04 | 2025 | Prolia, Evenity |
| Medicem INC. | $16.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.05 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.